News | Stents | March 24, 2016

NIRTRAKS Study of Novel Coronary Stent Enrolls First Patient

Data will be collected from 131 patients across eight U.S. sites

Medinol, NIRTRAKS Study, NIRxcell Stent System, first patient

Image courtesy of Medinol

March 24, 2016 — Medinol announced the enrollment of their first patient in the U.S. NIRTRAKS Study. NIRTRAKS is a post marketing, non-randomized study of the NIRxcell Stent System in patients with coronary artery disease indicated for percutaneous coronary intervention (PCI). 

The study objective is to collect and analyze additional information about the safety and effectiveness of the NIRxcell stent in the treatment of de novo lesions in native coronary arteries in the U.S. population. The data will be collected from 131 patients with a primary endpoint of target vessel failure (TVF) at three years.  Manesh Patel, M.D., Duke University Hospital, is the national principal investigator (PI) for the study with a total of eight sites participating across the United States.  

"We are pleased with the start of the NIRTRAKS study, allowing us to gather further data on this unique and highly innovative technology.  While we have been utilizing the NIRxcell commercially for the last nine months, we are excited to further understand the clinical application this new design has for our patients," said Patel.

The first patient was enrolled into the study on Jan. 15, and over the last few weeks, site enrollment has continued to increase.

The NIRTRAKS study will look to build on the results of the PIONIR prospective study, which saw the NIRxcell stent demonstrate a 5.1 percent target lesion revascularization (TLR) rate at nine months, according to Medinol’s Chief Scientific Officer Yoram Richter, Ph.D.

The NIRxcell Stent is Medinol's fifth-generation coronary stent. It features the WiZeCell stent design, offering an optimal balance between vessel conformability, scaffolding integrity and radial strength.  The Flexx2 delivery system with a spring tip ensures ease of delivery even in the most tortuous and calcified anatomies.  NIRxcell became commercially available in the United States in January 2015.

NIRxcell Stent technology serves as a platform for Medinol's eDES (elastomer drug-eluting stent) currently in clinical trials in the U.S., Canada, Europe and Israel.

For more information: www.medinol.com

Related Content

Among high-risk, chronic, coronary patients who undergo angioplasty, there were no additional benefits from ticagrelor compared to the current standard of care clopidogrel. #AHA #AHA20 #AHA2020
News | Cath Lab | November 16, 2020
November 16, 2020 — The use of the more potent antiplatelet medication ticagrelor (Brilinta) was not superior to clop
A large subgroup analysis of the VOYAGER PAD randomized clinical trial showed neither a mortality risk nor benefit associated with the use of paclitaxel drug-coated devices (DCD) in the treatment of peripheral artery disease (PAD). The study also found that the benefit of rivaroxaban use on reducing ischemic limb and cardiovascular outcomes was consistent regardless of whether a DCD was used. #TCT2020 #TCTconnect
Feature | Cath Lab | October 18, 2020
October 18, 2020 – A large subgroup analysis of a randomized clinical trial showed neither a mortality risk nor benef
A longitudinal vessel assessment may demonstrate co-existence of multiple plaque morphologies on OCT, including superficial calcification with thrombus, healed plaque, plaque rupture, lipidic plaque with a thin capped fibrous atheroma (TCFA). #TCTconnect #TCT2020

A longitudinal vessel assessment may demonstrate co-existence of multiple plaque morphologies on OCT, including superficial calcification with thrombus, healed plaque, plaque rupture, lipidic plaque with a thin cap fibro-atheroma (TCFA).

News | Cath Lab | October 18, 2020
October 18, 2020 – Data from the...
The DISRUPT CAD III study showed intravascular lithoplasty from Shockwave Medical was effective in breaking up calcified coronary lesions. #TCT2-0

The DISRUPT CAD III study showed intravascular lithoplasty from Shockwave Medical was effective in breaking up calcified coronary lesions.

Feature | Cath Lab | October 16, 2020
October 15, 2020 — Shockwave Medical's Intravascular Lithotripsy (IVL) system to treat severely calcified coronary ar
Videos | Cath Lab | October 16, 2020
This is an example pf the Shockwave Medical Intravascular Lithotripsy (IVL) catheter system designed to break up heav
Videos | Cath Lab | July 15, 2020
Richard Botto, CVT, RCSA, chief cardiovascular technologist, division of cardiology, cardiac cath lab, offers an over
Videos | Cath Lab | July 13, 2020
The Vieussens’ arterial ring (VAR) is a connection between the conus artery and the left anterior descending (LAD) co
News | Cath Lab | July 06, 2020
July 6, 2020 — Black patients who undergo percutaneous coronary intervention (PCI) are at an increased risk for major